Tai Patricia, Veness Michael, Prajapati Vimal H, Jones Thachuthara Aoife, Lian Jidong, Assouline Avi, Yu Edward, Joseph Kurian
Department of Oncology, University of Saskatchewan, Saskatoon, SK S7N 5A2, Canada.
Department of Oncology, University of Sydney, Sydney, NSW 2050, Australia.
Curr Oncol. 2025 Mar 28;32(4):202. doi: 10.3390/curroncol32040202.
(1) Background: Knowledge regarding the optimal radiotherapy dose for Merkel-cell carcinoma (MCC) remains limited. (2) Methods: Following a PubMed search, equivalent doses in 2 Gy fractions (Gy2) were compared. (3) Results: Of the 949 patients, 939 were evaluable, with 728 (77.5%) cases localized to the primary site and 171 irradiated without chemotherapy. The overall local recurrence rate (LRR) was 23% (40/171). After definitive radiotherapy with EQD2 < 50 Gy2 versus ≥50 Gy2, the LRRs were 23.1% (3/13) and 12.5% a(1/8), respectively ( = 0.0004). (4) Conclusions: For definitive radiotherapy, EQD2 < 50 Gy2 demonstrates a significantly higher LRR than ≥50 Gy2 ( = 0.0004). This study is clinically useful and unique with stratification by definitive/adjuvant settings and positive/negative resection margins. A future prospective multicenter study is needed to determine the optimal radiotherapy doses.
（1）背景：关于默克尔细胞癌（MCC）最佳放疗剂量的知识仍然有限。（2）方法：在进行PubMed搜索后，比较了2Gy分割剂量下的等效剂量（Gy2）。（3）结果：949例患者中，939例可评估，其中728例（77.5%）局限于原发部位，171例未接受化疗进行了放疗。总体局部复发率（LRR）为23%（40/171）。在等效剂量2（EQD2）<50 Gy2与≥50 Gy2的根治性放疗后，局部复发率分别为23.1%（3/13）和12.5%（1/8）（P = 0.0004）。（4）结论：对于根治性放疗，EQD2<50 Gy2的局部复发率显著高于EQD2≥50 Gy2（P = 0.0004）。本研究通过根治性/辅助治疗设置以及切缘阳性/阴性分层，具有临床实用性和独特性。需要未来进行前瞻性多中心研究来确定最佳放疗剂量。
